-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Infliximab in ulcerative colitis
Review
(3221) Views (700) Full article downloads
Authors: Avi Levin, Oren Shibolet
Published Date September 2008
Volume 2008:2(3) Pages 379 - 388
DOI: http://dx.doi.org/10.2147/BTT.S2249
Avi Levin, Oren Shibolet
Gastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, Israel
Abstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC.
Keywords: infliximab, ulcerative colitis, anti-TNF-α antibody, crohn’s disease
Readers of this article also read:
Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy
Therapeutic vaccines for malignant brain tumors
Biologic targeting in the treatment of inflammatory bowel diseases
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Corrigendum - Functional mobility and balance in community dwelling elderly submitted to multisensory versus strength exercises
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Corrigendum
Erratum
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




